Altria Just Raised Its 6.4% Dividend—Can It Keep Paying?
Altria just handed shareholders a bigger check for the 60th time in 56 years, but negative operating cash flow last quarter and a vape unit bleeding billions in impairments raise a real question about whether the streak has a price.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Altria just wrote another check to shareholders, and it’s a bigger one. Altria (NYSE:MO | MO Price Prediction) declared a $1.11 per share quarterly dividend with an ex-dividend date of September 15, 2026 and a payment date of October 9, 2026. That is a raise from the prior $1.06 quarterly rate, pushing the annualized forward payout to $4.44. Against a current share price of $69.85, the forward yield sits near 6.4%. The question this scorecard tackles: does the cash actually support the check?
Why the Dividend Earns High Marks
Altria just logged its 60th dividend increase in the past 56 years, putting it firmly in Dividend King territory (we ranked ten of them by valuation in a free report here: 10 Dividend Kings to Buy Now and Hold Forever), and management called out that $3.6 billion was paid in dividends in the first half of 2026 alone. Coverage looks solid at the annual level. For fiscal 2025, operating cash flow was $9.29 billion against dividend payouts of $6.96 billion, a roughly 75% cash payout that leaves room for the $335 million spent on buybacks in the first half.
The core smokable business is still a cash machine powering this dividend. Adjusted smokable OCI margins ran 64.9% in the first half, price realization hit 4.5% in Q2, and Marlboro’s premium share held steady at 59.6%. Debt-to-EBITDA at 1.9 times sits right at management’s roughly 2x target.
Cracks in the Cash Machine
Domestic cigarette shipments fell 10.0% in full-year 2025, and even after adjusting for trade inventories, Q2 2026 volumes still declined 4.5%. Marlboro’s total retail share slipped 1.5 share points year over year. The next-generation bets have bruises: NJOY absorbed $2.2 billion in non-cash impairments, and oral tobacco adjusted OCI fell 8% in Q2 as on! pouch investment ramped.
Operating cash flow was negative $51 million in Q2 2026 against a $1.54 billion dividend payout. That pattern (weak Q2 operating cash flow) has now happened in 2021, 2022, 2024, and 2026, so timing rather than solvency is the likely explanation. Still, negative stockholders’ equity of negative $3.2 billion is a real balance-sheet flag.
Final Grade: B
Full-year 2026 adjusted EPS guidance of $5.61 to $5.72 comfortably covers the $4.44 annualized dividend, and management flagged the payout as its “primary vehicle” for shareholder returns. The 6% yield is real, the streak is real, and cash coverage works today. The B, rather than an A, reflects a shrinking core, an impairment-scarred vape unit, and a pouch business still spending to defend share. Income investors get paid well while management races the volume clock.
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
